GENETIC TECH LTD-SP ADR (GENE)

US37185R4065 - ADR

2.18  -0.07 (-3.11%)

After market: 2.2 +0.02 (+0.92%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GENETIC TECH LTD-SP ADR

NASDAQ:GENE (4/25/2024, 7:00:01 PM)

After market: 2.2 +0.02 (+0.92%)

2.18

-0.07 (-3.11%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap8.39M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GENE Daily chart

Company Profile

Genetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 60 full-time employees. The firm offers predictive genetic testing and risk assessment tools. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its GeneType and EasyDNA brands. The firm operates through three segments: EasyDNA, AffinityDNA, and geneType / Corporate. The EasyDNA segment relates to EasyDNA branded test sales and expenses. The AffinityDNA segment relates to AffinityDNA branded test sales and expenses. The geneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. GeneType also offers integrated risk testing for a range of serious conditions. EasyDNA and AffinityDNA offer deoxyribonucleic acid (DNA) testing services.

Company Info

GENETIC TECH LTD-SP ADR

60-66 Hanover St, Fitzroy

Melbourne VICTORIA 3065

P: 61394151135

CEO: Simon Morriss

Employees: 60

Website: https://www.gtglabs.com/

GENE News

News Image4 days ago - Genetic Technologies LtdGenetic Technologies Announces Closing of US$2 Million Registered Direct Offering
News Image4 days ago - Genetic Technologies LtdGenetic Technologies Announces Closing of US$2 Million Registered Direct Offering

Genetic Technologies Announces Closing of $2 Million Registered Direct Offering...

News Image8 days ago - Genetic Technologies LtdGenetic Technologies Announces $2 Million Registered Direct Offering
News Image8 days ago - Genetic Technologies LtdGenetic Technologies Announces $2 Million Registered Direct Offering

Genetic Technologies Announces $2 Million Registered Direct Offering...

News Image9 days ago - Genetic Technologies LtdNew Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
News Image10 days ago - Genetic Technologies LtdGeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year

GENE Twits

Here you can normally see the latest stock twits on GENE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example